Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LPTX | Common Stock | Exercise of in-the-money or at-the-money derivative security | $601 | +213 | $2.82 | 213 | Nov 13, 2024 | Direct | F1 | |
holding | LPTX | Common Stock | 262K | Nov 13, 2024 | See footnote | F2 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | LPTX | Warrant (Right to Buy) | Exercise of in-the-money or at-the-money derivative security | $0 | -213 | -100% | $0.00 | 0 | Nov 13, 2024 | Common Stock, $0.001 par value per share | 213 | $2.82 | Direct | F1 |
Id | Content |
---|---|
F1 | On November 13, 2024, James Cavanaugh exercised a warrant to purchase 213 shares of the Issuer's common stock at an exercise price of $2.82 per share. |
F2 | These shares are held by the HCV VIII Trust (the "HCV Trust"). The reporting person is a beneficiary of the HCV Trust and may be deemed to have beneficial ownership of the 261,840 shares of Common Stock held by the HCV Trust. The reporting person disclaims beneficial ownership of such shares of Common Stock held by the HCV Trust, except to the extent of the reporting person's proportionate pecuniary interest in such shares of Common Stock. |